Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
22 9월 2023 - 5:05AM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced that
Sekar Kathiresan, M.D., co-founder and chief executive officer,
will participate in a fireside chat at the 2023 Cantor Global
Healthcare Conference on Thursday, September 28, 2023 at 10:55 a.m.
ET in New York.
A live webcast will be available in the investor section of the
company's website at www.vervetx.com. The webcast will be archived
for 30 days following the presentation.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s initial three programs – VERVE-101, VERVE-102, and
VERVE-201 – target genes that have been extensively validated as
targets for lowering low-density lipoprotein cholesterol (LDL-C), a
root cause of cardiovascular disease, in order to durably reduce
blood LDL-C levels. VERVE-101 and VERVE-102 are designed to
permanently turn off the PCSK9 gene in the liver and are being
developed initially for heterozygous familial hypercholesterolemia
(HeFH) and ultimately to treat atherosclerotic cardiovascular
disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is
designed to permanently turn off the ANGPTL3 gene in the liver and
is initially being developed for homozygous familial
hypercholesterolemia (HoFH) and ultimately to treat patients with
refractory hypercholesterolemia. For more information, please visit
www.vervetx.com.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactDan Budwick 1AB
Mediadan@1abmedia.com
Verve Therapeutics (NASDAQ:VERV)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Verve Therapeutics (NASDAQ:VERV)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024